Related Experiment Video

Updated: Sep 21, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.9K

Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?

Shu Ding1, Yu Rao1, Qianjin Lu2,3

  • 1Department of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tongzipo Road, Changsha, 410013, Hunan, China.

Cellular & Molecular Immunology
|May 31, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.5K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.3K

Related Experiment Videos

Last Updated: Sep 21, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.9K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.5K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Reasons for Upadacitinib Discontinuation and Risk of Recurrence in the Treatment of Atopic Dermatitis.

Dermatitis : contact, atopic, occupational, drug·2026

Multimodal computational framework resolves B cell maturation in autoimmunity and ageing.

Journal of autoimmunity·2026

Efficacy of the Bispecific Anti-BAFF/IL-21 Antibody CZ105 Bis2 in Models of Systemic Lupus Erythematosus.

Arthritis & rheumatology (Hoboken, N.J.)·2026

NICE: A Two-Step Non-Invasive Framework for Embryo cfDNA Read Enrichment and Quality Assessment.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Associations between physical activity and dietary live microbe intake with non-alcoholic fatty liver disease: findings from the NHANES, 2007-2018.

Journal of global health·2026

Four healthy lifestyle behaviours and adult-onset AD risk: A prospective Study from UK Biobank.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells.

Cellular & molecular immunology·2026

HnRNPK restrains memory precursor and plasma cell differentiation to control germinal center B-cell output.

Cellular & molecular immunology·2026

p97-mediated proteostasis is a checkpoint for late-stage thymocyte positive selection.

Cellular & molecular immunology·2026

Targeting the FOXP3-T-bet interaction to restore Treg stability in IFN-γ-driven autoimmunity.

Cellular & molecular immunology·2026

The NLRP3 inflammasome at the crossroads of innate immune signaling and cell death.

Cellular & molecular immunology·2026

ABTB1, as an E3 ubiquitin ligase, suppresses Th17 cell differentiation and mitigates autoimmune inflammation by promoting STAT3 ubiquitination and degradation.

Cellular & molecular immunology·2026

A single-center retrospective study evaluating the efficacy of anlotinib plus temozolomide for recurrent glioma based on real-world data.

Translational cancer research·2026

Mechanism of miR-188-5p enhancing radioresistance in nasopharyngeal carcinoma by targeting PTEN to activate the PI3K/Akt signaling pathway.

Translational cancer research·2026

A real-world feasibility and safety study of anlotinib monotherapy in heavily pretreated or temozolomide-ineligible recurrent malignant glioma.

Translational cancer research·2026

Remodeling the tumor immune microenvironment: mechanisms of crosstalk between regulated cell death macrophages.

Frontiers in immunology·2026

Stem cell-derived exosomes preserve diabetic islet function: a systematic review and meta-analysis of preclinical studies.

Biophysics reports·2026

Pathological role of deubiquitinating enzymes in lung cancer: recent insights and advances.

American journal of cancer research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us